Literature DB >> 1986827

Clinical uses of gonadotropin-releasing hormone analogues.

R F Casper1.   

Abstract

Gonadotropin-releasing hormone (Gn-RH) analogues are synthetic derivatives of the native hypothalamic peptide with alterations in their chemical structure that result in changes in biologic activity. Several Gn-RH agonists are available for clinical use, and all act through the same mechanism: first to stimulate and then to inhibit gonadotropin and gonadal steroid secretion by downregulating the pituitary Gn-RN receptors. This review should provide clinicians with a working knowledge of the physiologic and pharmacokinetic features of Gn-RH agonists. Although over 2000 articles concerning Gn-RH analogues have been published I chose to review only those that were the first to report a novel clinical application. Gn-RH agonists have proved to be extremely efficacious in treating gonadal steroid-dependent problems such as endometriosis, uterine leiomyoma, precocious puberty and prostate and breast cancers, and they have resulted in very few side effects. Long-term use may, however, lead to skeletal calcium loss in women as a consequence of hypoestrogenism. Further research is needed to prevent this and maintain clinical efficacy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1986827      PMCID: PMC1452955     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  37 in total

1.  Treatment of leiomyomata with intranasal or subcutaneous leuprolide, a gonadotropin-releasing hormone agonist.

Authors:  A J Friedman; R L Barbieri; B R Benacerraf; I Schiff
Journal:  Fertil Steril       Date:  1987-10       Impact factor: 7.329

2.  Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial.

Authors:  M R Henzl; S L Corson; K Moghissi; V C Buttram; C Berqvist; J Jacobson
Journal:  N Engl J Med       Date:  1988-02-25       Impact factor: 91.245

3.  Doppler assessment of uterine blood flow changes in patients with fibroids receiving the gonadotropin-releasing hormone agonist Buserelin.

Authors:  W H Matta; I Stabile; R W Shaw; S Campbell
Journal:  Fertil Steril       Date:  1988-06       Impact factor: 7.329

4.  Clinical and hormonal effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovarian disease.

Authors:  K Steingold; D De Ziegler; M Cedars; D R Meldrum; J K Lu; H L Judd; R J Chang
Journal:  J Clin Endocrinol Metab       Date:  1987-10       Impact factor: 5.958

5.  Pregnancies after IVF when high tonic LH is reduced by long-term treatment with GnRH agonists.

Authors:  M C Macnamee; C M Howles; R G Edwards
Journal:  Hum Reprod       Date:  1987-10       Impact factor: 6.918

6.  Follicular stimulation for in vitro fertilization using pituitary suppression and human menopausal gonadotropins.

Authors:  S G Awadalla; C I Friedman; N W Chin; W Dodds; J M Park; M H Kim
Journal:  Fertil Steril       Date:  1987-11       Impact factor: 7.329

7.  Does calcium supplementation prevent postmenopausal bone loss? A double-blind, controlled clinical study.

Authors:  B Riis; K Thomsen; C Christiansen
Journal:  N Engl J Med       Date:  1987-01-22       Impact factor: 91.245

8.  A comparison of the effects of Buserelin versus danazol on plasma lipoproteins during treatment of pelvic endometriosis.

Authors:  A M Dlugi; S Rufo; J F D'Amico; M M Seibel
Journal:  Fertil Steril       Date:  1988-05       Impact factor: 7.329

9.  Bone mineral density in women with endometriosis before and during ovarian suppression with gonadotropin-releasing hormone agonists or danazol.

Authors:  I S Tummon; A Ali; M E Pepping; E Radwanska; Z Binor; W P Dmowski
Journal:  Fertil Steril       Date:  1988-05       Impact factor: 7.329

10.  Comparative effects of cyproterone acetate or a long-acting gonadotropin-releasing hormone agonist in polycystic ovarian disease.

Authors:  B Couzinet; N Le Strat; S Brailly; G Schaison
Journal:  J Clin Endocrinol Metab       Date:  1986-10       Impact factor: 5.958

View more
  5 in total

Review 1.  Functional domains of the gonadotropin-releasing hormone receptor.

Authors:  S C Sealfon; R P Millar
Journal:  Cell Mol Neurobiol       Date:  1995-02       Impact factor: 5.046

Review 2.  Current and future applications of GnRH, kisspeptin and neurokinin B analogues.

Authors:  Robert P Millar; Claire L Newton
Journal:  Nat Rev Endocrinol       Date:  2013-07-02       Impact factor: 43.330

Review 3.  Diversity of actions of GnRHs mediated by ligand-induced selective signaling.

Authors:  Robert P Millar; Adam J Pawson; Kevin Morgan; Emilie F Rissman; Zhi-Liang Lu
Journal:  Front Neuroendocrinol       Date:  2007-08-23       Impact factor: 8.606

4.  Reproductive hormonal treatments for mood disorders in women.

Authors:  Peter J Schmidt; David R Rubinow
Journal:  Dialogues Clin Neurosci       Date:  2002-06       Impact factor: 5.986

5.  Pseudotumour Cerebri Presentation in a Child Under the Gonadotropin-Releasing Hormone Agonist Treatment.

Authors:  Ülkü Gül; Ayşe Kaçar Bayram; Mustafa Kendirci; Nihal Hatipoğlu; Deniz Okdemir; Hakan Gümüş; Selim Kurtoğlu
Journal:  J Clin Res Pediatr Endocrinol       Date:  2016-04-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.